Although EGFR tyrosine kinase inhibitors (EGFR TKIs) significantly improve clinical outcomes in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations, such as exon 19 deletion and the L858R mutation, almost all mutant EGFR-positive NSCLC patients ultimately acquire resistance to EGFR TKIs after approximately 1–2 years [1]. Here, EGFR is linked to non-small cell lung carcinoma.